What was the weight loss percentage in the retatrutide trial?

Participants on the highest dose (12 mg) lost an average of 28.3% of body weight over 80 weeks.

When will retatrutide be available on the market?

Eli Lilly has not announced a launch date yet, but it is expected to file for FDA approval next year.

How did the results affect Eli Lilly's stock?

Eli Lilly's stock (LLY) rose after the positive results announcement, reflecting investor optimism.

Eli Lilly's Retatrutide Shows 28.3% Weight Loss in Phase 3 Trial

Eli Lilly (LLY) reported positive Phase 3 results for its obesity drug retatrutide, with participants on the highest dose losing an average of 28.3% of body weight over 80 weeks. The stock rose following the announcement.

June 8, 2026

2 min read

Source: Quartz

Key Numbers

weight loss percentage

28.3%

trial duration weeks

Eli Lilly (ticker: LLY) announced positive Phase 3 trial results for its obesity drug retatrutide, with participants on the highest dose losing an average of 28.3% of body weight over 80 weeks. The stock jumped on the news.

Trial Details

The Phase 3 study showed that retatrutide, a GLP-1/GIP/glucagon receptor agonist, achieved significant weight loss compared to placebo. The highest dose (12 mg) was the most effective, with a mean weight loss of 28.3%.

Mechanism of Action

Retatrutide targets three hormone receptors involved in appetite regulation and metabolism, leading to reduced food intake and increased calorie burning.

Competitive Landscape

Retatrutide competes with other obesity drugs like Wegovy (Novo Nordisk) and Mounjaro (Eli Lilly). Its triple-action mechanism may offer superior efficacy.

Availability and Pricing

Eli Lilly has not yet announced a launch date or pricing for retatrutide, but it is expected to seek FDA approval next year.

Stock Impact

Eli Lilly's stock (LLY) rose significantly after the announcement, reflecting investor optimism about retatrutide's potential in the growing obesity market.

Frequently Asked Questions

Retatrutide is an experimental weight loss drug from Eli Lilly that activates three hormone receptors (GLP-1, GIP, glucagon) to regulate appetite and metabolism.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.